Objective-Hypertriglyceridemia and fatty liver are common in patients with type 2 diabetes, but the factors connecting alterations in glucose metabolism with plasma and liver lipid metabolism remain unclear. Apolipoprotein CIII (apoCIII), a regulator of hepatic and plasma triglyceride metabolism, is elevated in type 2 diabetes. In this study, we analyzed whether apoCIII is affected by altered glucose metabolism. Methods and Results-Liver-specific insulin receptor-deficient mice display lower hepatic apoCIII mRNA levels than controls, suggesting that factors other than insulin regulate apoCIII in vivo. Glucose induces apoCIII transcription in primary rat hepatocytes and immortalized human hepatocytes via a mechanism involving the transcription factors carbohydrate response element-binding protein and hepatocyte nuclear factor-4␣. ApoCIII induction by glucose is blunted by treatment with agonists of farnesoid X receptor and peroxisome proliferator-activated receptor-␣ but not liver X receptor, ie, nuclear receptors controlling triglyceride metabolism. Moreover, in obese humans, plasma apoCIII protein correlates more closely with plasma fasting glucose and glucose excursion after oral glucose load than with insulin. Conclusion-Glucose induces apoCIII transcription, which may represent a mechanism linking hyperglycemia, hypertriglyceridemia, and cardiovascular disease in type 2 diabetes. (Arterioscler Thromb Vasc Biol. 2011;31:513-519.)
T ype 2 diabetes is a progressive disease that is due to increased insulin resistance and progressive pancreatic failure. Type 2 diabetic patients often display lipid metabolism abnormalities (namely hypertriglyceridemia; low highdensity lipoprotein-cholesterol levels; and increased small, dense low-density lipoprotein particles) that result in increased cardiovascular disease risk. Epidemiological studies identified hypertriglyceridemia as an independent risk factor for atherosclerosis. 1 The hypertriglyceridemia is due to hepatic overproduction of triglyceride-rich very-low-density lipoprotein particles, 2 as well as impaired intravascular catabolism as a result of decreased lipoprotein lipase activity. 2
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Apolipoprotein CIII (apoCIII) is a 79-amino-acid glycoprotein synthesized in the liver and the intestine 3 that controls triglyceride metabolism in humans 4 and mice. 5 ApoCIII is a component of triglyceride-rich lipoproteins, low-density lipoprotein, and high-density lipoprotein. 6 Plasma triglyceride and apoCIII concentrations positively correlate in normo-and hypertriglyceridemic subjects. [7] [8] [9] [10] ApoCIII gene deficiency results in a hypotriglyceridemia because of an accelerated catabolism of triglyceride rich-lipoproteins, 4, 5 whereas apo-CIII overexpression in mice leads to hypertriglyceridemia. 11 In vitro and in vivo studies have established that apoCIII delays the catabolism of triglyceride-rich lipoproteins by inhibiting lipoprotein lipase 12, 13 and inhibits the hepatic uptake of triglyceride-rich remnants. 14, 15 Moreover, the rate of hepatic apoCIII production correlates with the level of very-low-density lipoprotein-triglyceride production. 16 Recently, 2 variant alleles of the apoCIII gene have been associated with the development of nonalcoholic fatty liver disease and insulin resistance, suggesting a role in intrahepatic fat metabolism. 17 ApoCIII is also an independent predictor of cardiovascular disease and longevity. 18 ApoCIII levels in diabetic patients correlate with atherosclerosis, 19, 20 and apoCIII exerts direct proatherogenic activities in vascular cells. 21 In line with this, a null mutation in human apoCIII gene correlates with lower coronary artery calcification scores. 22 Plasma apoCIII levels are pharmacologically modulated by fibrates and statins, which lower triglycerides in type 2 diabetics. [23] [24] [25] Plasma free fatty acids stimulate apoCIII production in humans, 26 whereas insulin inhibits apoCIII expression in diabetic mice. 27, 28 However, the effects of glucose signaling on apoCIII have not yet been assessed.
Glucose modulates the transcription of genes involved in glycolysis and lipogenesis in the liver, 29 including liver pyruvate kinase (LPK) and fatty acid synthase (FAS), key enzymes of the glycolytic and lipogenic pathways. Promoter analysis has led to the identification of glucose-response DNA-regulatory sequences, called carbohydrate response elements, composed of 2 consensus 6-base-pair E-box motifs separated by 5 nucleotides. 30 Different transcription factors bind to carbohydrate response elements, 29 but glucose responsiveness appears mediated by the carbohydrate response element-binding protein (ChREBP). 31, 32 However, other transcription factors also participate in this response, including the nuclear receptors hepatocyte nuclear factor-4␣ (HNF-4␣) 33 and liver X receptors (LXRs). 34 Here, we studied the regulation of apoCIII gene expression by glucose using liver-specific insulin receptor-deficient (LIR-KO) mice, rat primary hepatocytes, and immortalized human hepatocytes (IHH). In addition, studies were performed in obese humans to assess the correlation between plasma apoCIII protein levels and glucose homeostasis.
Methods

Animal Experiment
Three-to 5-month-old male LIR-KO mice and their littermates 35 were euthanized either nonfasted, after 24 hours fasting, or after 24 hours fasting and 6 hours refeeding a high-carbohydrate diet (Harlan Teklad 88122) (6 to 8 mice/group) at 2:30 pm. Livers were snap frozen in liquid nitrogen.
Primary Rat Hepatocytes and IHH Experiments
Primary rat hepatocyte isolation and cell culture is described in the Supplemental Information, available online at http://atvb.ahajournals.org IHH 36 were incubated in low glucose medium supplemented with 10 mmol/L lactate or glucose with or without GW4064 (5 mol/L), ciprofibrate (100 mol/L), or T09001317 (1 mol/L) for 24 hours.
Each experiment was performed at least 3 times, each time with independent triplicates. Results from a representative experiment are shown.
ApoCIII Protein Measurement
Ninety-six-well plates were coated with rabbit antiserum, the wells were saturated with bovine serum albumin, and calibrators or supernatants were incubated in these antibody-coated wells. Goat anti-rat apoCIII IgGs (provided by PJ Dolphin, Halifax, Nova Scotia, Canada) were incubated overnight at 4°C, and then horseradish peroxidase-conjugated rabbit anti-goat immunoglobulins were incubated for 2 hours at 37°C. The plates were read at 450 nm using the SpectraMax 384plate reader (Molecular Devices). The total protein amount was determined by the Peterson method.
Transient Transfection Assays
Primary rat hepatocytes were transfected using JetPEI (Qbiogene, Illkirch, France) in glucose-free Dulbecco's modified Eagle's medium for 16 hours with the indicated pGL3-luciferase constructs and the Renilla reporter plasmid pRL-Null (Promega, Madison, WI). After transfection, cells were treated for 24 hours in glucose-free Dulbecco's modified Eagle's medium containing the indicated concentration of glucose and insulin.
IHH cells were transfected using DharmaFect1 (Dharmacon, Lafayette, CO) with 100 nmol/L of HNF-4␣ (D-003406-02 and -03; Dharmacon) or ChREBP (D-009253-01 and -02; Dharmacon) or LXR small interfering RNAs (siRNA) (M-003413-01 and M-003412-01; Dharmacon) in serum-, gentamicin-, and glutaminefree William's E medium. After 6 hours, medium was changed; 24 hours later, glucose stimulation was performed as described above.
Human Patient Cohort
The characteristics of the human patient cohort are presented in Supplemental Table I . White patients (nϭ91; mean age, 46Ϯ13 years; mean body mass index, 37.1Ϯ6.7 kg/m 2 ) visiting the obesity clinic of the Antwerp University Hospital were analyzed for fasting plasma glucose and blood glucose at 2 hours (BG-2H) after an oral glucose tolerance test. 37 Fasting insulin, C-peptide, and the area under the curve of insulin and glucose after the oral glucose tolerance test were measured. The study was approved by the ethical committee of the Antwerp University Hospital, and all patients gave their informed consent.
Results
Hepatic ApoCIII mRNA Is Lower in LIR-KO Mice
Because hepatic apoCIII mRNA is inhibited by insulin, 27, 28 we analyzed the impact of impaired liver insulin signaling on apoCIII expression in vivo using LIR-KO mice. Surprisingly, apoCIII mRNA levels were lower in LIR-KO compared with wild-type mice under all dietary conditions ( Figure 1A ). mRNA levels of the glycolytic enzyme LPK, 29 which is controlled by glucose, increased to a lesser extent in LIR-KO, indicating that LIR-KO mice have a blunted glucose response, likely because of a lack of insulin-induced glucokinase activity ( Figure 1B) . These data indicate that factors other than hepatic insulin signaling also contribute to apoCIII regulation in vivo.
Glucose Induces ApoCIII Transcription in Primary Rat Hepatocytes
To test the hypothesis that glucose regulates apoCIII gene expression, primary rat hepatocytes were incubated with high or low glucose concentrations. Glucose increased apoCIII protein secretion (Figure 2A ), as well as apoCIII mRNA, in a time-( Figure 2B ) and concentration-dependent manner (Figure 2C ). Pretreatment of primary rat hepatocytes with actinomycin D, a RNA polymerase II inhibitor, abolished the glucose-induced increase of apoCIII mRNA levels ( Figure  2D ), suggesting a transcriptional mechanism.
Transient transfection experiments in primary rat hepatocytes using the Ϫ1200/ϩ24 human apoCIII promoter, containing the hepatic enhancers driving apoCIII expression in human and rodent livers, 38 revealed an increase of apoCIII promoter activity in response to glucose ( Figure 2E ). Because glucose activates transcription via E-boxes, 30 computer-assisted analysis (Matinspector, Genomatix) was used, and E-box sequences conserved in the rat and human promoters were found in the distal Ϫ1050 and proximal C3P regions (Supplemental Figure IA and IB). Interestingly, glucose induced the binding of a complex only to the C3P probe (Supplemental Figure IC) . Transient transfection experiments using mutated C3P site constructs showed that the C3P region confers glucose responsiveness ( Figure 2F ). Thus, glucose induces apoCIII transcription in primary rat hepatocytes via the C3P region of the apoCIII gene promoter.
Glucose Induces ApoCIII in IHH
To investigate the regulation of apoCIII by glucose in human cells, IHH were studied. 36 Interestingly and unlike other human hepatocyte cell lines, such as the HepG2 hepatoma cell line, IHH cells respond to glucose, as illustrated by the induction of LPK gene expression in a glucose-dosedependent manner (data not shown). Incubation of IHH cells with glucose induced apoCIII mRNA ( Figure 3A Figure IIB) . The glucose-mediated apoCIII induction was abolished by actino-mycin D preincubation ( Figure 3A ). Transient transfection experiments showed that the activity of the Ϫ1200/ϩ24 apoCIII human promoter increased after glucose stimulation in IHH cells ( Figure 3D) . Moreover, the activity of the wild-type, but not the mutated C3P footprint, was also induced by glucose ( Figure 3E ).
HNF-4␣ and ChREBP But Not LXRs Mediate Glucose Induction of ApoCIII Expression
The C3P locus is a complex site that contains a direct repeat spaced by 1 nucleotide, a direct repeat spaced by 2 nucleotides, and 2 E-boxes (E-box) (Supplemental Figure IB) . The 2 direct repeat sites bind transcription factors of the nuclear receptor family. 38 HNF-4␣, which binds to the direct repeat spaced by 1 nucleotide site of the C3P footprint, 38 is involved in the glucose-regulated expression of genes such as those for LPK 39 and FAS. 33 To investigate whether HNF-4␣ is implicated in the induction of apoCIII gene expression by glucose, siRNA experiments were performed in IHH cells, and the expression of LPK and apoCIII was subsequently analyzed in conditions of low and high glucose concentrations. HNF-4␣ siRNA transfection reduced its basal and glucose-induced expression (Supplemental Figure IIIA) . Interestingly, LPK and apoCIII mRNA induction by glucose was lower on HNF-4␣ knockdown, suggesting that HNF-4␣ is at least partially implicated in the induction of apoCIII gene expression by glucose ( Figure 4A ).
SiRNA knockdown of ChREBP, a glucose-responsive transcription factor binding to E-boxes 32 Figure 4B ).
By contrast, siRNA knockdown of LXR␣ and LXR␤ (Supplemental Figure IIIC) , also implicated in the response to glucose, 34, 40 did not influence apoCIII induction by glucose, whereas the induction of a classical LXR target gene, ABCG8, by the LXR agonist T0901317 was diminished (Supplemental Figure IIID) .
ApoCIII Induction by Glucose Can Be Pharmacologically Modulated
Because apoCIII expression is regulated by nuclear receptor agonists, 24, 41 we investigated whether their activation inhibits glucose induction of apoCIII expression. IHH cells were incubated in medium containing low or high glucose concentrations in presence of either dimethyl sulfoxide (vehicle), the farnesoid X receptor (FXR) agonist GW4064, the peroxisome proliferator-activated receptor-␣ (PPAR␣) agonist ciprofibrate, or the LXR agonist T0901317. Glucose induction of apoCIII gene expression was partially abolished by GW4064 ( Figure 5A ) and ciprofibrate ( Figure 5B ) treatment, whereas LXR agonist treatment did not have an effect ( Figure 5C ).
ApoCIII Protein Correlates Positively With Fasting Plasma Glucose and Plasma Glucose Excursion After a Glucose Bolus in Overweight Subjects, Independently of Gender, Age, and Body Mass Index
To determine whether apoCIII is also modulated by parameters of glucose homeostasis in humans, plasma apoCIII protein levels were measured in drug-naive overweight subjects and correlated with different metabolic parameters related to glucose metabolism. After controlling for gender, age, and body mass index, plasma apoCIII protein levels correlated positively with fasting plasma glucose (rϭ0.28; Pϭ0.007) and glucose excursion after a glucose bolus (rϭ0.46; PϽ0.001) (Supplemental Figure IV and Table) . By contrast, plasma apoCIII protein levels did not correlate with fasting plasma insulin and plasma insulin excursion (Table) . Moreover, plasma apoCIII protein levels did not correlate with plasma fasting C-peptide concentrations. These results suggest that apoCIII protein levels specifically positively correlate with parameters of glucose metabolism in humans.
Discussion
Type 2 diabetic patients, who are at high cardiovascular risk, often display hypertriglyceridemia associated with increased plasma apoCIII concentrations. 20 ApoCIII exerts multiple proatherogenic effects. By impairing triglyceride metabolism, apoCIII stimulates the accumulation of atherogenic remnants. Moreover, apoCIII may exert direct atherogenic actions, because it stimulates monocyte adhesion to endothelial cells. 21 Our study identifies a novel mechanism linking glucose and plasma triglyceride metabolism via the regulation of apoCIII expression by glucose. ApoCIII gene expression is lower in livers of LIR-KO mice that do not respond to insulin and show decreased glucose signaling, as illustrated by an impaired LPK induction after high-carbohydrate refeeding. Moreover, apoCIII gene expression is induced in rat and human hepatocytes by high glucose concentrations. This effect occurs at the transcriptional level and involves the transcription factors ChREBP and HNF-4␣. Finally, we show that plasma apoCIII protein levels correlate positively with both plasma fasting glucose and glucose excursion after a glucose bolus in overweight patients.
Indirect links between glucose homeostasis and apoCIII metabolism have already been established. First, apoCIIIdeficient mice exhibit an aggravated diet-induced insulin resistance. 42 Moreover, apoCIII expression is downregulated by insulin. 27, 28, 43 However, a direct link between apoCIII and glucose had not been demonstrated until now. Our results showing that apoCIII gene expression is regulated by glucose via a transcriptional mechanism provide a mechanistic explanation for the recently raised hypothesis that a low-fat, high-carbohydrate diet could lead to an overproduction of apoCIII protein in humans. 44 This regulation occurs via the C3P footprint in the apoCIII promoter, which is different from the insulin response site, with a structural organization closely resembling the organization of the LPK promoter. 39 Moreover, the mechanism by which glucose affects apoCIII transcription implies the activation of the same transcription factors as LPK, eg, ChREBP and HNF-4␣. ChREBP mediates glucose induction of key glycolytic and lipogenic enzymes. 31, 32 The nuclear receptor HNF-4␣ is a partner of the glucose response complex on the LPK promoter, 39 necessary for an optimal glucose responsiveness of the FAS gene. 33 Because of its interaction with SREBP-1c 45 and ChREBP, 33 HNF-4␣ functions as a scaffold protein to assemble the transcriptional machinery required for insulin and glucose responsiveness. 33 Intriguingly, apoCIII gene expression is regulated in an opposite manner by insulin (negatively) and glucose (positively). Most genes in the glycolytic (LPK) and lipogenic (fatty acid synthase, acetyl-coenzyme A carboxylase) pathways are regulated positively both by insulin and glucose. 29 It is tempting to speculate that glucose induction of apoCIII expression may contribute to a lower lipolysis, and resulting in a lower fatty acid uptake by peripheral tissues and thus contributing to an increase in peripheral glucose handling as alternative substrate for energy metabolism. The observation that apoCIII-deficient mice exhibit an aggravated insulin resistance 42 is in line with this hypothesis. However, chronic elevation of apoCIII will increase plasma lipids and consequently the risk of atherosclerosis development. We speculate that in insulin resistance associated with hyperglycemia, as in type 2 diabetes, insulin no longer represses apoCIII expression, whereas chronic glucose elevation enhances its expression, leading to an overproduction of apoCIII, resulting in an increased risk for atherosclerosis, via either hypertriglyceridemia or direct vascular effects of apoCIII. 21 ApoCIII gene expression is downregulated at the transcriptional level by several nuclear receptors. FXR, PPAR␣, and Rev-erb␣ inhibit apoCIII gene expression. 24, 41, 46 Interestingly, the induction of apoCIII gene expression by glucose can be inhibited pharmacologically by activators of the nuclear receptors PPAR␣ and FXR but not by LXR agonists. FXR represses basal apoCIII expression by displacing HNF-4␣ from its site upstream of the proximal region in the enhancer region. 41 PPAR␣ binds to the C3P footprint and inhibits apoCIII transcription by displacing HNF-4␣, 24 as well as by inhibiting forkhead box O 1 activation of apoCIII transcription via the insulin-responsive element. 47 PPAR␣mediated inhibition of glucose-induced apoCIII expression could thus be a result of a combination of molecular mechanisms.
In overweight subjects, plasma apoCIII protein levels were positively correlated with fasting glucose and glucose excursion, but not insulin and insulin excursion. These observations suggest, although they do not prove, that apoCIII levels are predominantly under control of glucose but not insulin.
In summary, our results show that apoCIII gene expression is increased by glucose stimulation. These data may provide a mechanism involved in the development of diabetic hypertriglyceridemia. Interference with glucose-induced apoCIII expression may constitute an additional mechanism to correct atherogenic dyslipidemia.
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